Nuvectis Pharma, Inc. (NVCT) investor relations documents from the company's IR site: 4 presentations; latest deck 2026-07-05. Read in-app with summaries. First-party data.
https://storage.googleapis.com/vendorgroup-assets/site/06c2e337-3f91-4e38-96b4-7264f3c8b7c9/2026/07/06/6a4b2a9181712e94d: Nuvectis Pharma is a precision medicine company developing NXP100, an oral Factor B inhibitor for PNH and IgAN, with two NDAs currently under regulatory review in China.
| Published | Type | Document |
|---|---|---|
| 2026-07-05 | Presentation | https://storage.googleapis.com/vendorgroup-assets/site/06c2e337-3f91-4e38-96b4-7264f3c8b7c9/2026/07/06/6a4b2a9181712e94d |
| 2026-05-10 | Presentation | Corporate Presentation (May 2026) |
| 2025-12-20 | Presentation | NXP900 Phase 1b KOL Event (December 2025) |
| Presentation | Presentation |
NVCT overview · NVCT earnings · NVCT financials · NVCT KPIs · NVCT documents · NVCT ownership · NVCT peers
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.